The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01E | Antiglaucoma preparations and miotics | |
| 4 | S01EE | Prostaglandin analogues | |
| 5 | S01EE01 | Latanoprost |
| Active Ingredient | Description | |
|---|---|---|
| Latanoprost |
The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MONOPOST Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| XALATAN Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| XALATAN Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
